CEO Dr. Michael Wyand and Co-Founder Dr. Vishal Bansal joined Recovery Now host Kim Justus to discuss the science behind OXE103, how Ghrelin works in the brain, and why current concussion treatment needs to evolve beyond "sit in front of the window and watch a squirrel."
The Phase 2a results showed an 85% responder rate versus 33% for standard care at the University of Kansas Medical Center. The next step is a 160-patient Phase 2b trial that could position OXE103 as the first FDA-approved treatment for persistent concussion symptoms.
Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market.
Invest now